Bio-Techne Corporation (TECH)

Market Cap	11.16B
Revenue (ttm)	1.16B
Net Income (ttm)	168.07M
Shares Out	158.67M
EPS (ttm)	1.05
PE Ratio	67.01
Forward PE	37.68
Dividend	$0.32 (0.45%)
Ex-Dividend Date	Aug 19, 2024

Volume	783,913
Open	70.78
Previous Close	71.24
Day's Range	69.80 - 70.92
52-Week Range	51.79 - 85.57
Beta	1.27
Analysts	Buy
Price Target	80.67 (+14.65%)
Earnings Date	Oct 30, 2024

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%.

Analyst Forecast

According to 9 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $80.67, which is an increase of 14.65% from the latest price.

Price Target

$80.67

(14.65% upside)

Analyst Consensus: Buy